VJHemOnc is committed to improving our service to you

ASH 2019 | Final phase 2 results of LCL161 for myelofibrosis

VJHemOnc is committed to improving our service to you

Naveen Pemmaraju

At the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL, the final results of phase 2 trial of LCL161 for myelofibrosis (MF) were presented by Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX. Here Dr Pemmaraju discusses the findings from the use of this novel oral SMAC mimetic/IAP antagonist in intermediate to high-risk MF (NCT02098161).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter